Products for Research Use Only

NOSH-aspirin

CAT: 0804-HY-150038Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-150038Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
NOSH-aspirin (NBS-1120) is an orally active hybrid molecule that releases nitric oxide and hydrogen sulfide. NOSH-aspirin inhibits pancreatic cancer cell proliferation and induces apoptosis. NOSH-aspirin inhibits cancer cell growth and suppresses NF-κB and FoxM1 in a mouse model of pancreatic cancer. NOSH-aspirin also alleviates motor deficits and dopaminergic neuron degeneration in a rat model of Parkinson's disease. NOSH-aspirin reduces neuroinflammation caused by microglial and astrocytic activation. NOSH-aspirin can be used in research on cancers such as pancreatic cancer and neurological diseases such as Parkinson's disease[1][2][3].
CAS Number
1357362-67-4
Product Name Alternative
NBS-1120
UNSPSC
12352005
Target
Apoptosis; NF-κB
Related Pathways
Apoptosis; NF-κB
Field of Research
Cancer; Neurological Disease
Smiles
O=C(OC1=CC=C(C(SS2)=CC2=S)C=C1)C3=CC=CC=C3OC(CCCO[N+]([O-])=O)=O
Molecular Formula
C20H15NO7S3
Molecular Weight
477.53
References & Citations
[1]Lee M, et al. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders. Glia. 2013 Oct;61 (10) :1724-34.|[2]Chattopadhyay M, et al. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS. Biochem Pharmacol. 2020 Jun;176:113857. |[3]Firouzan B, et al. NOSH-aspirin (NBS-1120) attenuates motor defects and dopaminergic neuron degeneration in a rat model of Parkinson's disease. Eur J Pharmacol. 2025 Sep 5;1002:177733.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported